Home Subcutaneous Infusion of Furosemide in Advanced Decompensated Heart Failure Article (PDF Available) in Revista Espanola de Cardiologia 67(3):241-2 · March 2014 with 107 Reads 1. Rev Esp Cardiol (Engl Ed). 2013 Dec;66(12):1002-4. doi: 10.1016/j.rec.2013.06.008. Epub 2013 Sep 17. Subcutaneous infusion of furosemide administered by elastomeric pumps for decompensated heart failure treatment: initial experience. Updated 11/2017 S.Grimsdale HFNS Page 1/3 Guideline for Administration of Subcutaneous Furosemide in the Community Setting in Bradford, Airedale, Wharfdale and Craven. PALLIATIVE CARE MEDICATIONS COMMONLY USED SUBCUTANEOUSLY Copyright © 2004 Capital Health Regional Pharmacy Services. Capital Health/Caritas and Authors are not. Prior use of subcutaneous furosemide pump or current use of any subcutaneous pump, on-body infusion devices or patients who give regimented injections at the intended site of the furosemide infusion device CLINICAL RESEARCH Subcutaneous Furosemide in Heart Failure Pharmacokinetic Characteristics of a Newly Buffered Solution Domenic A. Sica, MD,a Pieter Muntendam, MD, bRene L. Myers, PHD, Jozine M. ter Maaten, MD, PHD,c Subcutaneous infusion of buffered furosemide in the outpatient setting or home may help to reduce the burden of heart failure. Parenteral diuretics form the cornerstone of decongestion in heart failure. However, parenteral therapy routinely requires emergency room or inpatient care. A novel buffered furosemide formulation with neutral pH was developed to offer “hospital-strength” diuresis. One in every 33 Americans will be living with heart failure and its consequences in just over a decade. HF is the decreasing ability of the heart to pump blood effectively, which in turn limits the supply of oxygen-rich blood and impairs the body’s capacity to function properly. Administer the dose by continuous subcutaneous infusion via a Graseby MS26 (24 hour) syringe driver. It may be infused over 24 hours or alternatively over 6 to 8 hours and end stage heart failure with subcutaneous furosemide via continuous subcutaneous infusion. The guidance applies to patients requiring subcutaneous furosemide at the near end of life stage of their condition. The decision to change from oral to subcutaneous furosemide would be made by the palliative care team, cardiologist or GP and supported by the heart failure specialist nurses and.